Abstracts tagged "Biomarkers"

Abstract Number: 1168 • ACR Convergence 2025
Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
Karis Lee¹, Min Kyung Lee² and Stanley Naides³, ¹Labcorp, Orlando, FL, ²Labcorp, Durham, NC, ³Labcorp, Dana Point, CA

Background/Purpose: Interstitial lung disease (ILD) is frequent in systemic autoimmune rheumatic diseases (SARDs) and is associated with poor prognosis. The prevalence of ILD is approximately…
Abstract Number: 0629 • ACR Convergence 2025
Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
Pankti Mehta¹, Fadi Kharouf², Virginia Carrizo Abarza³, Qixuan Li⁴, Dafna D. Gladman⁵, Zahi Touma⁶ and Laura Whitall Garcia⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: We aimed to study the prevalence of subtypes of lupus arthritis and determine their association with clinical features, serology, and type I interferon signature.Methods:…
Abstract Number: 0842 • ACR Convergence 2025
Association of urinary biomarkers with histological features in diagnostic and per-protocol repeat kidney biopsies in lupus nephritis
Andrea Fava¹, CHEN-YU LEE¹, Carla Guthridge², Dionysis Nikolopoulos³, Julius Lindblom⁴, Farah Tamirou⁵, Michelle Petri⁶, Joel Guthridge², Frederic Houssiau⁷ and Ioannis Parodis⁸, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Cliniques universitaires Saint-Luc, Brussels, Belgium, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷CUSL, BRUSSELS, Belgium, ⁸Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Persistent intrarenal inflammation despite immunosuppression drives kidney damage and functional decline in lupus nephritis (LN). Yet, current guidelines do not recommend repeat biopsy to…
Abstract Number: 0516 • ACR Convergence 2025
Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)
Pierre-Marie Duret¹, Maude Bouchard-Marmen², Loukas Chatzis³, Margherita Giannini⁴, François Severac⁵, FELTEN Renaud⁶, Dan Levy⁷, Benoit Nespola⁸, Emmanuel Chatelus⁹, Emmanuelle Dernis¹⁰, Valerie Devauchelle¹¹, Philippe Dieude¹², Jean-Jacques Dubost¹³, Anne-Laure Fauchais¹⁴, Bernard Geny¹⁵, Eric Hachulla¹⁶, Claire larroche¹⁷, Véronique Le Guern¹⁸, Jacques Morel¹⁹, Aleth Perdriger²⁰, Carine Salliot²¹, Alain SARAUX²², Damien Sène²³, Jean Sibilia²⁴, SORDET Christelle⁶, Olivier Vittecoq²⁵, Raphaele Seror²⁶, Gaetane Nocturne²⁷, Andreas Goules²⁸, Athanasios G. Tzioufas²⁹, Xavier Mariette³⁰, Jacques-eric GOTTENBERG³¹ and Alain Meyer³², ¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²CHU de Québec, Québec, QC, Canada, ³Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Greece, Athens, Greece, ⁴Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁵Département de Santé Publique, Groupe Méthodes en Recherche Clinique (GMRC), CHU de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁶Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁷Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁸Laboratoire d’Immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁹Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹⁰Service de Rhumatologie, Centre Hospitalier Le Mans, Le Mans, Le Mans, France, ¹¹UBO, Brest, France, ¹²Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ¹³Service de Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand, Clermont-Ferrand, France, ¹⁴UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, France, ¹⁵UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, ¹⁶Service de Médecine Interne et Immunologie Clinique, CHU de Lille, Hôpital Claude Huriez, Lille, Lille, France, ¹⁷Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, ¹⁸Cochin hospital, Paris, France, ¹⁹CHU and University of Montpellier, Montpellier, France, ²⁰Rennes University, Rennes, France, ²¹CHR orleans, Orleans, France, ²²CHU Brest, Brest, France, ²³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ²⁴Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, ²⁵Service de Rhumatologie & CIC-CRB ¹⁴⁰⁴, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, ²⁶Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ²⁸Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, Greece, ²⁹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, ³⁰Université Paris-Saclay, Le Kremlin Bicetre, France, ³¹Hautepierre Hospital, STRASBOURG, Alsace, France, ³²Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France
Background/Purpose: There is an unmet clinical need for identification of novel biomarkers of systemic complications and lymphoma in primary Sjögren disease (SD). Anti-cytosolic 5'-nucleotidase 1A…
Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…
Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Benjamin Jones¹, Miles Smith², Rufei Lu², Carla Guthridge², Susan Macwana², Wade DeJager³, Nancy Olsen⁴, Catriona Wagner⁵, Judith James², David Karp⁶ and Joel Guthridge², ¹Oklahoma State University, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁶UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…
Abstract Number: 2649 • ACR Convergence 2025
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Bernard Rubin², Mohan Purushothaman², Wade DeJager³, Susan Macwana⁴, Joel Guthridge⁴, Stan Kamp⁴, Nancy Redinger⁴, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yangfen Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane Kamen⁸, Jill Buyon⁹, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Medical University of South Carolina, Johns Island, SC, ⁹NYU Grossman School of Medicine, New York, NY
Background/Purpose: Immune dysregulation propels systemic lupus erythematosus (SLE) pathogenesis. Capturing it as lab-based screening tests could help prioritize SLE patients for early intervention and proactive…
Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…
Abstract Number: 2236 • ACR Convergence 2025
Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors
EVRIPIDIS KALTSONOUDIS¹, Nikolaos Kougkas², Panagiota Karagianni³, Tereza Memi⁴, Nikolaos Koletsos⁵ and Eleftherios Pelechas⁶, ¹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ²⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ³BioAcuHealth.gr, Ioannina, Ioannina, Greece, ⁴University Hospital of Ioannina, Ioannina, Ioannina, Greece, ⁵School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁶Hatzikosta General Hospital of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Rheumatoid arthritis (RA) can coexist with other autoimmune disorders such as Sjögren’s syndrome and systemic lupus erythematosus (SLE). In these cases, the terms secondary…
Abstract Number: 1942 • ACR Convergence 2025
An Agnostic Evaluation of Serum Proteins Discriminates the Severity of Ultrasound Arthritis in SLE Patients
Robert Clancy¹, Philip Carlucci², Alberto Nordmann-Gomes³, Leila Khalili⁴, Wei Tang⁵, Giovanna Rosas Chavez⁴, Stephen Suh⁶, Laura Geraldino-Pardilla¹, Yevgeniya Gartshteyn⁷, Joel Guthridge⁸, Judith James⁸ and Anca Askanase⁴, ¹Columbia University, New York, NY, ²New York University School of Medicine, New York, NY, ³Columbia University Irving Medical Center, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵Westchester Medical Center, Valhalla, NY, ⁶Columbia University Irving Medical Center, New York City, NY, ⁷Columbia University Medical Center, Glen Rock, NJ, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Inflammatory arthritis occurs in up to 90% of patients and is a main cause of SLE work-related disability. SLE arthritis is difficult to evaluate…
Abstract Number: 1772 • ACR Convergence 2025
Correlation between Soluble Checkpoint Molecules and Disease Activity in Autoimmune Diseases
Kosaku Murakami¹, Akiko Yoshida², Hitoshi Uga³, Shuji Sumitomo⁴, Koichiro Ohmura⁵, Ryosuke Hiwa⁶, Tomohiro Kozuki⁷, Mao Kuroishi³, Chihiro Suminaka³, Mirei Shirakashi⁶, Hideaki Tsuji⁸, Shuji Akizuki⁶, Ran Nakashima⁶, Hajime Yoshifuji⁶, Akira Onishi⁹, Masao Tanaka⁹, Akio Morinobu¹⁰, Kenji Chamoto⁷ and Tasuku Honjo⁷, ¹Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ²Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Central Research Laboratories, Sysmex corporation, Kobe, Hyogo, Japan, ⁴Kobe City Medical Center General Hospital, Kobe city, Hyogo, Japan, ⁵Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁷Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁰Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Soluble checkpoint molecules (sCM) may be involved in the pathophysiology of autoimmune diseases by inhibiting the suppressive signals of immune cell activation through binding…
Abstract Number: 1611 • ACR Convergence 2025
Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Yusuke Ushio¹, Hiromi Shimada², Taichi Miyagi³, Koichi Sugihara², Mao Mizusaki², Rina Mino², Kanako Chujo³, Naoto Manabe³, Mayuko Wada², Shusaku Nakashima² and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita District, Kagawa, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Avacopan, an oral C5a receptor antagonist, offers a promising glucocorticoid (GC)-sparing option for patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Although…
Abstract Number: 1362 • ACR Convergence 2025
Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
Mohammad Daud Khan¹, Matthew Dapas², Salina T Dominguez¹, Tyler Therron³, Kathleen Aren⁴, Mary Carns⁵, Hadijat Makinde⁵, Arthur M Mandelin¹, Eric M Ruderman¹, John F Seagrist⁵, Ruth Misha¹, Carla Marie Cuda⁵, Harris R Perlman⁵ and Deborah Rachelle Winter⁶, ¹Northwestern University, Chicago, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Northwestern University, Chicago, IL, ⁶Northwestern University, Skokie, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by persistent synovial inflammation and progressive joint damage. Selecting an effective biologic therapy remains a…
Abstract Number: 1166 • ACR Convergence 2025
Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis
Julie Borchsenius¹, Maria Dons², Morten Sengeløv³, Flemming Olsen⁴, Caroline Espersen⁴, Kristoffer Skaarup³, Mats Lassen⁴, Niklas Johansen⁴, Filip Davidovski³, Manan Pareek⁴, Brittany Weber⁵, Claus Zachariae⁶, Lone Skov⁶ and Tor Biering-Sørensen³, ¹CTCPR / Center for translational cardiology and pragmatic research trials, Charlottenlund, Denmark, ²Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴CTCPR / Center for translational cardiology and pragmatic research trials, Copenhagen, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Individuals with psoriasis are at increased risk of developing heart disease. Echocardiographic parameters of impaired left atrial (LA) strain (Peak atrial contraction and longitudinal…
Abstract Number: 0620 • ACR Convergence 2025
The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
Luis Daniel Fajardo Hermosillo and María Karina Lizbeth López Ramírez, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, GUADALAJARA, Jalisco, Mexico
Background/Purpose: Remission in Systemic Lupus Erythematosus (SLE) is described by the Definition of Remission in SLE (DORIS), but it is hardly achieved in clinical practice,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].